Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5702624 | Urologic Oncology: Seminars and Original Investigations | 2017 | 5 Pages |
Abstract
Concomitant PCa is occurring in>50% of RC specimens with a significant proportion having characteristics (GS, pathological stage) of clinically relevant disease. Adverse bladder histology is a risk factor for both PCa and biochemical PSA recurrence. Follow-up analyses after RC should include PSA measurements also in low-risk PCa as a considerable number of patients develop biochemical recurrence and metastases from PCa partly ending up with death related to PCa in patients suffering from BC.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Isabel M.D., Ph.D., Willi Ph.D., Wolfgang M.D., Renate M.D.,